SlideShare una empresa de Scribd logo
1 de 60
Computational Chemistry Methods SAR, Pharmacophores & Protein Docking  Terry S. Clayton 03/10/10
Warning!
Outline ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Molecular Databases ChemDraw for Excel ChemDBsoft
SAR
Betacarbolines
Pharmacophore ,[object Object],[object Object],[object Object],Ehrlich. Dtsch. Chem. Ges. 1909, 42: p.17 Wermuth, C.G.; Ganellin, C.R.; Lindberg, P.; Mitscher, L.A. (1998). "Glossary of terms used in medicinal chemistry".  Pure Appl. Chem.
2D pharmacophore Martin et al.  J. Med. Chem. 1992,35,4105-4117
Hardware for Modeling ,[object Object],[object Object],[object Object],[object Object],[object Object]
Excluded volume analysis Allen et al.  Journal  of Medicinal Chemistry, 1990, Vol. 33, No. 9
H1 and A2 Descriptor
Ro15-1788
3D QSAR ,[object Object],[object Object],[object Object],[object Object],[object Object]
Molecular Databases ChemDraw for Excel ChemDBsoft
MacroModel  ,[object Object],[object Object]
Gaussian  ,[object Object],[object Object]
CoMFA
Validation ,[object Object],[object Object],[object Object],[object Object]
Troubleshooting ,[object Object],[object Object],[object Object],[object Object],[object Object]
Electrostatic CoMFA Map
Steric CoMFA Map
DS electrostatic Map
 
Prediction Accuracy Huang. Dissertation 1998. UWM
Pharmacophore Descriptors
BzR Pharmacophore L1
Cook’s Unified Pharmacophore Figure III . The pyrazolo [3,4-c]quinolin-3-one ligand CGS-9896 (dotted line), diazepam (thick line), and planar diindoles (thin line) fitted to a schematic representation of the inclusive pharmacophore model for the BzR. The descriptors H1 and H2 designate hydrogen bond donor sites on the receptor protein while A2 represents a hydrogen bond acceptor site necessary for potent inverse agonist activity  in vivo . L1, L2, L3 and LDi are four lipophilic regions in the binding
Excluded volume analysis Allen et al.  Journal  of Medicinal Chemistry, 1990, Vol. 33, No. 9
Classes of Ligands Employed for the Study of Pharmacophore/ Receptor Models of BzR Subtypes
Pharmacophore  ,[object Object],[object Object]
Overlay of Included Volume of Pharmacophore/Receptor Model for   and   Receptor Subtypes Orthogonal views of the overlap of the included volumes of the pharmacophore/ receptor models for a1b3g2 (green) and a5b3g2 (red) receptor subtypes(overlap in yellow).
L 2 L 2 A 1 A 1 H 1 H 2 H 2 H 1 L Di L Di L 3 L 3 L 1 L 1 L 2 L 2 A 1 A 1 H 1 H 2 H 2 H 1 L Di L Di L 3 L 3 L 1 L 1 L 2 L 2 A 1 A 1 H 1 H 2 H 2 H 1 L Di L Di L 3 L 3 L 1 L 1 L 2 L 2 A 1 A 1 H 1 H 2 H 2 H 1 L Di L Di L 3 L 3 L 1 L 1 L 2 L 2 A 1 A 1 H 1 H 2 H 2 H 1 L Di L Di L 3 L 3 L 1 L 1 ) Orthogonal views of the overlap (yellow) volumes of  a1b3g2 (red)  and   a2b3g2 (green) b)   Orthogonal views of the overlap (yellow) volumes of  a2b3g2 (red)   and   a3b3g2 (green)  c)   Orthogonal views of the overlap (yellow) volumes of  a4b3g2 (red)   and   a6b3g2 (green) d)  Orthogonal views of the overlap (yellow) volumes of  a1b3g2 (red)  and  a6b3g2 (green) e)  Orthogonal views of the overlap (yellow) volumes of  a5b3g2 (red)  and  a1b3g2 (green) f) Diazepam and the unified pharmacophore descriptors depicted in the included volume of the a1b3g2 subtype.
The 8-Phenyl Ligands Aligned in the Included Volume of the Pharmacophore/Receptor Model for the    (blue) and    (red) Subtypes
Xli-356
R and S Conformation S Conformation  R Conformation
Today’s Pharmacophore ,[object Object],[object Object],[object Object],[object Object],[object Object]
HipHop Module of Catalyst Viijayan et al. J. Mol. Graphics and Modeling, 27 (2008) 286-298.
Examples Micheli et al.  J. Med. Chem. , Articles ASAP February 19, 2010  Aronov J. Med. Chem. , 2006, 49 (23), pp 6917–6921 Maestro MOE
3D Database Searching ,[object Object],[object Object],[object Object],[object Object],[object Object],Clark, Expert Opinion on Drug Discovery  2008, Vol. 3, No. 8 : Pages 841-851
Homology Modeling ,[object Object],[object Object],[object Object],[object Object]
GABA A  Receptor
Cross-section of GABA A  Receptor Absolute subunit arrangement of the a1b2g2 GABAA receptor when viewed from the synaptic cleft.  The GABA binding sites are located at the b+a- subunit interfaces and the modulatory Bz BS (Bz) is located at the a+g- subunit interface.18, [i] [i]  Pritchett, D., Sontheimer, H., Shivers, B., Ymer, S., Kettenmann, H., Schofield, P., and Seeburg, P., Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology,  Nature ,  1989 , 338, 582-585.
ACBP XRAY Brejc et al.  Nature   2001 ,  411 , 269-276.
ACBP   Subunit Belongs  to the same LGIC family as GABA A Template for GABA A !!!!
AcBP Sequence ,[object Object],[object Object],[object Object],[object Object],Data Table 3. Amino Acid Sequence of the alpha 1 subunit of the rat GABA A  receptor   >sp|P62813|GBRA1_RAT Gamma-aminobutyric acid receptor subunit alpha-1 OS=Rattus norvegicus GN=Gabra1 PE=1 SV=1 MKKSRGLSDYLWAWTLILSTLSGRSYGQPSQDELKDNTTVFTRILDRLLDGYDNRLRPGL GERVTEVKTDIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFKGPMTVLRLNNLMASKI WTPDTFFHNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHACP LKFGSYAYTRAEVVYEWTREPARSVVVAEDGSRLNQYDLLGQTVDSGIVQSSTGEYVVMT THFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISAR NSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGYAWDGKSVVPEKPKKVKDPL IKKNNTYAPTATSYTPNLARGDPGLATIAKSATIEPKEVKPETKPPEPKKTFNSVSKIDR LSRIAFPLLFGIFNLVYWATYLNREPQLKAPTPHQ
Sequence Alignment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Swiss Model
Refinements ,[object Object],[object Object],[object Object],[object Object]
Further refinements ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Send to Swiss Server ,[object Object],[object Object],[object Object]
GABA Ion Channel
GABA ligand docking
Protein Binding Site  
AutoDock 4.2 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Protein ,[object Object],[object Object],[object Object],[object Object],[object Object]
Define binding site
Molecular Modeling
Recommendation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Thank you
Benzodiazepine Conformation   Scheme 1. Dynamic Chirality of  1a - c  and Stereochemical Cooperativity in  2b  (    G       Values Were Determined by  1 H NMR Spectroscopy (Coalescense))  Copyright © 2006 American Chemical Society

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Quantitative structure - activity relationship (QSAR)
Quantitative  structure - activity  relationship (QSAR)Quantitative  structure - activity  relationship (QSAR)
Quantitative structure - activity relationship (QSAR)
 
2D QSAR DESCRIPTORS
2D QSAR DESCRIPTORS2D QSAR DESCRIPTORS
2D QSAR DESCRIPTORS
 
QSAR
QSARQSAR
QSAR
 
Chemical data
Chemical dataChemical data
Chemical data
 
Virendra
VirendraVirendra
Virendra
 
CoMFA CoMFA Comparative Molecular Field Analysis)
CoMFA CoMFA Comparative Molecular Field Analysis)CoMFA CoMFA Comparative Molecular Field Analysis)
CoMFA CoMFA Comparative Molecular Field Analysis)
 
QSAR by Faizan Deshmukh
QSAR by Faizan DeshmukhQSAR by Faizan Deshmukh
QSAR by Faizan Deshmukh
 
3d qsar
3d qsar3d qsar
3d qsar
 
3 d qsar approaches structure
3 d qsar approaches structure3 d qsar approaches structure
3 d qsar approaches structure
 
Qsar by hansch analysis
Qsar by hansch analysisQsar by hansch analysis
Qsar by hansch analysis
 
Qsar
QsarQsar
Qsar
 
QSAR quantitative structure activity relationship
QSAR quantitative structure activity relationship QSAR quantitative structure activity relationship
QSAR quantitative structure activity relationship
 
Introduction to Drug Design
 Introduction to Drug Design Introduction to Drug Design
Introduction to Drug Design
 
Qsar UMA
Qsar   UMAQsar   UMA
Qsar UMA
 
SAR & QSAR
SAR & QSARSAR & QSAR
SAR & QSAR
 
QSAR
QSARQSAR
QSAR
 
Quantitative Structure Activity Relationship (QSAR)
Quantitative Structure Activity Relationship (QSAR)Quantitative Structure Activity Relationship (QSAR)
Quantitative Structure Activity Relationship (QSAR)
 
3 D QSAR Approaches and Contour Map Analysis
3 D QSAR Approaches and Contour Map Analysis3 D QSAR Approaches and Contour Map Analysis
3 D QSAR Approaches and Contour Map Analysis
 
2D - QSAR
2D - QSAR2D - QSAR
2D - QSAR
 
Qsar by hansch analysis
Qsar by hansch analysisQsar by hansch analysis
Qsar by hansch analysis
 

Destacado

Perspective on QSAR modeling of transport
Perspective on QSAR modeling of transportPerspective on QSAR modeling of transport
Perspective on QSAR modeling of transportSean Ekins
 
Pharmacophore Q&A
Pharmacophore Q&APharmacophore Q&A
Pharmacophore Q&ASean Ekins
 
Computer aided drug designing
Computer aided drug designingComputer aided drug designing
Computer aided drug designingMuhammed sadiq
 
AutoDock_vina_japanese_ver.2.0
AutoDock_vina_japanese_ver.2.0AutoDock_vina_japanese_ver.2.0
AutoDock_vina_japanese_ver.2.0Satoshi Kume
 
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan DiseasesUsing In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan DiseasesSean Ekins
 
Computational Biology - Signaling networks and drug repositioning
Computational Biology - Signaling networks and drug repositioningComputational Biology - Signaling networks and drug repositioning
Computational Biology - Signaling networks and drug repositioningLars Juhl Jensen
 
AutoDock_vina_japanese_ver.3.0
AutoDock_vina_japanese_ver.3.0AutoDock_vina_japanese_ver.3.0
AutoDock_vina_japanese_ver.3.0Satoshi Kume
 
AutoDock_vina_japanese_ver.1.0
AutoDock_vina_japanese_ver.1.0AutoDock_vina_japanese_ver.1.0
AutoDock_vina_japanese_ver.1.0Satoshi Kume
 
Drug Repositioning Workshop
Drug Repositioning WorkshopDrug Repositioning Workshop
Drug Repositioning WorkshopGenna Gerla
 
Repositioning Old Drugs For New Indications Using Computational Approaches
Repositioning Old Drugs For New Indications Using Computational ApproachesRepositioning Old Drugs For New Indications Using Computational Approaches
Repositioning Old Drugs For New Indications Using Computational ApproachesYannick Pouliot
 
AutoDock, AutoGrid, AutoDockTools (GUI), and Open Babel Tutorial
AutoDock, AutoGrid, AutoDockTools (GUI), and Open Babel TutorialAutoDock, AutoGrid, AutoDockTools (GUI), and Open Babel Tutorial
AutoDock, AutoGrid, AutoDockTools (GUI), and Open Babel TutorialJohn Cahill
 
Drug discovery strategy final draft
Drug discovery strategy   final draftDrug discovery strategy   final draft
Drug discovery strategy final draftanaelishockey
 
Software resources in drug design
Software resources in drug designSoftware resources in drug design
Software resources in drug designSurmil Shah
 
The computational method
The computational methodThe computational method
The computational methodLeebia Hurra
 
Episode 1 - Le système informatique au service du bon usage
Episode 1 - Le système informatique au service du bon usageEpisode 1 - Le système informatique au service du bon usage
Episode 1 - Le système informatique au service du bon usageAntarès
 

Destacado (20)

Perspective on QSAR modeling of transport
Perspective on QSAR modeling of transportPerspective on QSAR modeling of transport
Perspective on QSAR modeling of transport
 
Pharmacophore Q&A
Pharmacophore Q&APharmacophore Q&A
Pharmacophore Q&A
 
Computer aided drug designing
Computer aided drug designingComputer aided drug designing
Computer aided drug designing
 
Pharmacophore identification
Pharmacophore identificationPharmacophore identification
Pharmacophore identification
 
AutoDock_vina_japanese_ver.2.0
AutoDock_vina_japanese_ver.2.0AutoDock_vina_japanese_ver.2.0
AutoDock_vina_japanese_ver.2.0
 
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan DiseasesUsing In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
 
Computational Biology - Signaling networks and drug repositioning
Computational Biology - Signaling networks and drug repositioningComputational Biology - Signaling networks and drug repositioning
Computational Biology - Signaling networks and drug repositioning
 
AutoDock_vina_japanese_ver.3.0
AutoDock_vina_japanese_ver.3.0AutoDock_vina_japanese_ver.3.0
AutoDock_vina_japanese_ver.3.0
 
AutoDock_vina_japanese_ver.1.0
AutoDock_vina_japanese_ver.1.0AutoDock_vina_japanese_ver.1.0
AutoDock_vina_japanese_ver.1.0
 
Drug Repositioning Workshop
Drug Repositioning WorkshopDrug Repositioning Workshop
Drug Repositioning Workshop
 
Repositioning Old Drugs For New Indications Using Computational Approaches
Repositioning Old Drugs For New Indications Using Computational ApproachesRepositioning Old Drugs For New Indications Using Computational Approaches
Repositioning Old Drugs For New Indications Using Computational Approaches
 
Rabeprazole
RabeprazoleRabeprazole
Rabeprazole
 
AutoDock, AutoGrid, AutoDockTools (GUI), and Open Babel Tutorial
AutoDock, AutoGrid, AutoDockTools (GUI), and Open Babel TutorialAutoDock, AutoGrid, AutoDockTools (GUI), and Open Babel Tutorial
AutoDock, AutoGrid, AutoDockTools (GUI), and Open Babel Tutorial
 
Grupo 4 ppt
Grupo 4 pptGrupo 4 ppt
Grupo 4 ppt
 
Drug discovery strategy final draft
Drug discovery strategy   final draftDrug discovery strategy   final draft
Drug discovery strategy final draft
 
Software resources in drug design
Software resources in drug designSoftware resources in drug design
Software resources in drug design
 
The computational method
The computational methodThe computational method
The computational method
 
[4] drug discovery-lect-1
[4] drug discovery-lect-1[4] drug discovery-lect-1
[4] drug discovery-lect-1
 
Rabeprazole 20 medical ppt
Rabeprazole 20 medical pptRabeprazole 20 medical ppt
Rabeprazole 20 medical ppt
 
Episode 1 - Le système informatique au service du bon usage
Episode 1 - Le système informatique au service du bon usageEpisode 1 - Le système informatique au service du bon usage
Episode 1 - Le système informatique au service du bon usage
 

Similar a Cook2010web

RATIONAL DRUG DESIGN.pptx
RATIONAL DRUG DESIGN.pptxRATIONAL DRUG DESIGN.pptx
RATIONAL DRUG DESIGN.pptxPraveen kumar S
 
Summer 2015 REU Poster AK_FINAL
Summer 2015 REU Poster AK_FINALSummer 2015 REU Poster AK_FINAL
Summer 2015 REU Poster AK_FINALAndrew Kocian
 
Exploiting tertiary structure through local folds for crystallographic phasing
Exploiting tertiary structure through local folds for crystallographic phasingExploiting tertiary structure through local folds for crystallographic phasing
Exploiting tertiary structure through local folds for crystallographic phasingxrbiotech
 
PROGRAM PHASE IN LIGAND-BASED PHARMACOPHORE MODEL GENERATION AND 3D DATABASE ...
PROGRAM PHASE IN LIGAND-BASED PHARMACOPHORE MODEL GENERATION AND 3D DATABASE ...PROGRAM PHASE IN LIGAND-BASED PHARMACOPHORE MODEL GENERATION AND 3D DATABASE ...
PROGRAM PHASE IN LIGAND-BASED PHARMACOPHORE MODEL GENERATION AND 3D DATABASE ...Simone Brogi
 
Quantative Structure-Activity Relationships (QSAR)
Quantative Structure-Activity Relationships (QSAR)Quantative Structure-Activity Relationships (QSAR)
Quantative Structure-Activity Relationships (QSAR)Atai Rabby
 
IJBB-51-3-188-200
IJBB-51-3-188-200IJBB-51-3-188-200
IJBB-51-3-188-200sankar basu
 
RAD51 Drug Discovery (ACS Denver 2011)
RAD51 Drug Discovery (ACS Denver 2011)RAD51 Drug Discovery (ACS Denver 2011)
RAD51 Drug Discovery (ACS Denver 2011)Anthony Coyne
 
FFW 2016 Poster_Cristallo
FFW 2016 Poster_CristalloFFW 2016 Poster_Cristallo
FFW 2016 Poster_CristalloTara Cristallo
 
Proteome-wide covalent ligand discovery in native biological systems
Proteome-wide covalent ligand discovery in native biological systemsProteome-wide covalent ligand discovery in native biological systems
Proteome-wide covalent ligand discovery in native biological systemsMegha Majumder
 
Inferring microbial ecosystem function from community structure
Inferring microbial ecosystem function from community structureInferring microbial ecosystem function from community structure
Inferring microbial ecosystem function from community structureJeff Bowman
 
Randomizing genome-scale metabolic networks
Randomizing genome-scale metabolic networksRandomizing genome-scale metabolic networks
Randomizing genome-scale metabolic networksAreejit Samal
 
Bacteria Induced Cryptic Meroterpenoid Pathway in Pathogenic Aspergillus fumi...
Bacteria Induced Cryptic Meroterpenoid Pathway in Pathogenic Aspergillus fumi...Bacteria Induced Cryptic Meroterpenoid Pathway in Pathogenic Aspergillus fumi...
Bacteria Induced Cryptic Meroterpenoid Pathway in Pathogenic Aspergillus fumi...Debanjan Chatterjee
 
Quantitative Structure Activity Relationship
Quantitative Structure Activity RelationshipQuantitative Structure Activity Relationship
Quantitative Structure Activity RelationshipRaniBhagat1
 
CMB 426 Final Presentation
CMB 426 Final PresentationCMB 426 Final Presentation
CMB 426 Final PresentationAlexander Ward
 
Predicting Novel Metabolic Pathways through Subgraph Mining
Predicting Novel Metabolic Pathways through Subgraph MiningPredicting Novel Metabolic Pathways through Subgraph Mining
Predicting Novel Metabolic Pathways through Subgraph MiningKarthik Raman
 
MSc Final Project - Alvaro Diaz Mendoza
MSc Final Project - Alvaro Diaz MendozaMSc Final Project - Alvaro Diaz Mendoza
MSc Final Project - Alvaro Diaz MendozaAlvaro Diaz Mendoza
 

Similar a Cook2010web (20)

RATIONAL DRUG DESIGN.pptx
RATIONAL DRUG DESIGN.pptxRATIONAL DRUG DESIGN.pptx
RATIONAL DRUG DESIGN.pptx
 
Summer 2015 REU Poster AK_FINAL
Summer 2015 REU Poster AK_FINALSummer 2015 REU Poster AK_FINAL
Summer 2015 REU Poster AK_FINAL
 
Exploiting tertiary structure through local folds for crystallographic phasing
Exploiting tertiary structure through local folds for crystallographic phasingExploiting tertiary structure through local folds for crystallographic phasing
Exploiting tertiary structure through local folds for crystallographic phasing
 
PROGRAM PHASE IN LIGAND-BASED PHARMACOPHORE MODEL GENERATION AND 3D DATABASE ...
PROGRAM PHASE IN LIGAND-BASED PHARMACOPHORE MODEL GENERATION AND 3D DATABASE ...PROGRAM PHASE IN LIGAND-BASED PHARMACOPHORE MODEL GENERATION AND 3D DATABASE ...
PROGRAM PHASE IN LIGAND-BASED PHARMACOPHORE MODEL GENERATION AND 3D DATABASE ...
 
Quantative Structure-Activity Relationships (QSAR)
Quantative Structure-Activity Relationships (QSAR)Quantative Structure-Activity Relationships (QSAR)
Quantative Structure-Activity Relationships (QSAR)
 
Paper 3_3
Paper 3_3Paper 3_3
Paper 3_3
 
IJBB-51-3-188-200
IJBB-51-3-188-200IJBB-51-3-188-200
IJBB-51-3-188-200
 
RAD51 Drug Discovery (ACS Denver 2011)
RAD51 Drug Discovery (ACS Denver 2011)RAD51 Drug Discovery (ACS Denver 2011)
RAD51 Drug Discovery (ACS Denver 2011)
 
FFW 2016 Poster_Cristallo
FFW 2016 Poster_CristalloFFW 2016 Poster_Cristallo
FFW 2016 Poster_Cristallo
 
Proteome-wide covalent ligand discovery in native biological systems
Proteome-wide covalent ligand discovery in native biological systemsProteome-wide covalent ligand discovery in native biological systems
Proteome-wide covalent ligand discovery in native biological systems
 
Inferring microbial ecosystem function from community structure
Inferring microbial ecosystem function from community structureInferring microbial ecosystem function from community structure
Inferring microbial ecosystem function from community structure
 
Lanjutan kimed
Lanjutan kimedLanjutan kimed
Lanjutan kimed
 
Randomizing genome-scale metabolic networks
Randomizing genome-scale metabolic networksRandomizing genome-scale metabolic networks
Randomizing genome-scale metabolic networks
 
Bacteria Induced Cryptic Meroterpenoid Pathway in Pathogenic Aspergillus fumi...
Bacteria Induced Cryptic Meroterpenoid Pathway in Pathogenic Aspergillus fumi...Bacteria Induced Cryptic Meroterpenoid Pathway in Pathogenic Aspergillus fumi...
Bacteria Induced Cryptic Meroterpenoid Pathway in Pathogenic Aspergillus fumi...
 
Prediction of heparin binding sites on GAPDH
Prediction of heparin binding sites on GAPDHPrediction of heparin binding sites on GAPDH
Prediction of heparin binding sites on GAPDH
 
Quantitative Structure Activity Relationship
Quantitative Structure Activity RelationshipQuantitative Structure Activity Relationship
Quantitative Structure Activity Relationship
 
CMB 426 Final Presentation
CMB 426 Final PresentationCMB 426 Final Presentation
CMB 426 Final Presentation
 
Predicting Novel Metabolic Pathways through Subgraph Mining
Predicting Novel Metabolic Pathways through Subgraph MiningPredicting Novel Metabolic Pathways through Subgraph Mining
Predicting Novel Metabolic Pathways through Subgraph Mining
 
bace1-alzheimers paper
bace1-alzheimers paperbace1-alzheimers paper
bace1-alzheimers paper
 
MSc Final Project - Alvaro Diaz Mendoza
MSc Final Project - Alvaro Diaz MendozaMSc Final Project - Alvaro Diaz Mendoza
MSc Final Project - Alvaro Diaz Mendoza
 

Cook2010web

  • 1. Computational Chemistry Methods SAR, Pharmacophores & Protein Docking Terry S. Clayton 03/10/10
  • 3.
  • 4. Molecular Databases ChemDraw for Excel ChemDBsoft
  • 5. SAR
  • 7.
  • 8. 2D pharmacophore Martin et al. J. Med. Chem. 1992,35,4105-4117
  • 9.
  • 10. Excluded volume analysis Allen et al. Journal of Medicinal Chemistry, 1990, Vol. 33, No. 9
  • 11. H1 and A2 Descriptor
  • 13.
  • 14. Molecular Databases ChemDraw for Excel ChemDBsoft
  • 15.
  • 16.
  • 17. CoMFA
  • 18.
  • 19.
  • 23.  
  • 24. Prediction Accuracy Huang. Dissertation 1998. UWM
  • 27. Cook’s Unified Pharmacophore Figure III . The pyrazolo [3,4-c]quinolin-3-one ligand CGS-9896 (dotted line), diazepam (thick line), and planar diindoles (thin line) fitted to a schematic representation of the inclusive pharmacophore model for the BzR. The descriptors H1 and H2 designate hydrogen bond donor sites on the receptor protein while A2 represents a hydrogen bond acceptor site necessary for potent inverse agonist activity in vivo . L1, L2, L3 and LDi are four lipophilic regions in the binding
  • 28. Excluded volume analysis Allen et al. Journal of Medicinal Chemistry, 1990, Vol. 33, No. 9
  • 29. Classes of Ligands Employed for the Study of Pharmacophore/ Receptor Models of BzR Subtypes
  • 30.
  • 31. Overlay of Included Volume of Pharmacophore/Receptor Model for  and  Receptor Subtypes Orthogonal views of the overlap of the included volumes of the pharmacophore/ receptor models for a1b3g2 (green) and a5b3g2 (red) receptor subtypes(overlap in yellow).
  • 32. L 2 L 2 A 1 A 1 H 1 H 2 H 2 H 1 L Di L Di L 3 L 3 L 1 L 1 L 2 L 2 A 1 A 1 H 1 H 2 H 2 H 1 L Di L Di L 3 L 3 L 1 L 1 L 2 L 2 A 1 A 1 H 1 H 2 H 2 H 1 L Di L Di L 3 L 3 L 1 L 1 L 2 L 2 A 1 A 1 H 1 H 2 H 2 H 1 L Di L Di L 3 L 3 L 1 L 1 L 2 L 2 A 1 A 1 H 1 H 2 H 2 H 1 L Di L Di L 3 L 3 L 1 L 1 ) Orthogonal views of the overlap (yellow) volumes of a1b3g2 (red) and a2b3g2 (green) b) Orthogonal views of the overlap (yellow) volumes of a2b3g2 (red) and a3b3g2 (green) c) Orthogonal views of the overlap (yellow) volumes of a4b3g2 (red) and a6b3g2 (green) d) Orthogonal views of the overlap (yellow) volumes of a1b3g2 (red) and a6b3g2 (green) e) Orthogonal views of the overlap (yellow) volumes of a5b3g2 (red) and a1b3g2 (green) f) Diazepam and the unified pharmacophore descriptors depicted in the included volume of the a1b3g2 subtype.
  • 33. The 8-Phenyl Ligands Aligned in the Included Volume of the Pharmacophore/Receptor Model for the  (blue) and  (red) Subtypes
  • 35. R and S Conformation S Conformation R Conformation
  • 36.
  • 37. HipHop Module of Catalyst Viijayan et al. J. Mol. Graphics and Modeling, 27 (2008) 286-298.
  • 38. Examples Micheli et al. J. Med. Chem. , Articles ASAP February 19, 2010 Aronov J. Med. Chem. , 2006, 49 (23), pp 6917–6921 Maestro MOE
  • 39.
  • 40.
  • 41. GABA A Receptor
  • 42. Cross-section of GABA A Receptor Absolute subunit arrangement of the a1b2g2 GABAA receptor when viewed from the synaptic cleft. The GABA binding sites are located at the b+a- subunit interfaces and the modulatory Bz BS (Bz) is located at the a+g- subunit interface.18, [i] [i] Pritchett, D., Sontheimer, H., Shivers, B., Ymer, S., Kettenmann, H., Schofield, P., and Seeburg, P., Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology, Nature , 1989 , 338, 582-585.
  • 43. ACBP XRAY Brejc et al. Nature 2001 , 411 , 269-276.
  • 44. ACBP  Subunit Belongs to the same LGIC family as GABA A Template for GABA A !!!!
  • 45.
  • 46.
  • 48.
  • 49.
  • 50.
  • 53. Protein Binding Site  
  • 54.
  • 55.
  • 58.
  • 60. Benzodiazepine Conformation   Scheme 1. Dynamic Chirality of 1a - c and Stereochemical Cooperativity in 2b (   G    Values Were Determined by 1 H NMR Spectroscopy (Coalescense)) Copyright © 2006 American Chemical Society

Notas del editor

  1. Homology modeling , also known as comparative modeling of protein refers to constructing an atomic-resolution model of the " target " protein from its amino acid sequence and an experimental three-dimensional structure of a related homologous protein (the " template ").
  2. Pyridodiindoles- note the loss in binding when R7 is methyl Phenylpyrazoloquinolinones
  3. 3 substituted ethers
  4. International Union of Pure and Applied Chemistry
  5. Here we are studying how betacarbolines fit in the lipopohilic pocket. The excluded receptor volume was generated by using the MVOL option of SYBYL 5.22 by subtracting the union of the volume of the “actives” from the union of volume of the “inactives”.
  6. Introduced 2 descriptors in in 1992. Places the hydrogen bond donor 1.84 A away from Nitrogen and A2 1.84 A away from the indole proton Inverse agonist bccm
  7. Antagonist- the earliest fit of a benzo in the developing pharmacophore with an imidazo Nitrogen coordinating with ideal bond lengths at 1.84 A and the carbonyl lone pair adjusted to 135 degrees from ( 120)
  8. basis set in chemistry is a set of functions used to create the molecular orbitals
  9. Monte Carlo Methods and the Metropolis Criterion Other search methods can be much more efficient for sampling conformational space and determining low-energy structures of a protein, such as stochastic searches involving "importance sampling": Start from an initial conformation, and minimize this structure with respect to the energy. Choose an arbitrary number of torsional angles from the initial conformation, vary them by a random amount, and then minimize this conformation. Use a criterion based on the energy to retain or discard this move (see below). If retained, continue; if discarded, go back to step 1. Compare the resulting structure against all structures previously found. If it does not match any of them, then store this structure as a unique one. Return to Step 2 and continue. Stop the search procedure when no new structures are found. Monte Carlo (MC) and Molecular Dynamics (MD) or Stochastic Dynamics (SD) use distinct methods to generate conformational states. In MC changes are assigned to the system by randomly modifying a few degrees of freedom at a time; the atoms are moved truly randomly, not deterministically. This methods allows for significant thermal fluctuations and sampling of higher energy structures, thus producing a wide spectrum of conformational states economicaly.
  10. Scf=tight- rigorous algorithm to a achieve identical population of low energy minimizations. Scf-qc is a less rigorour algorithm used in larger proteins that “ fail to converge”
  11. PLS IS USEFUL IN MULTIVARIATE SYSTEMS.
  12. BCCM (I), pyridodiindole 3, and 3H-2- phenyl-2,5-dihydropyrazolo[4,3-clquinolin-3-on(e4 1). Red and yellow contours surround regions where a more negative electlostatic interaction is predicted to increase dfinity
  13. Red – do not want steric interaction. Green/yellow- steric interaction is good
  14. Note the CoMFA does not show that negative electrostatic at carbonyl enhances affinity..This is because all ligands used in the comfa were of this scaffold. YOU CANT SEE DIFFERENCES IF YOUR DATASET IS ALL THE SAME.
  15. pyrazoloquinoline ligand CGS-8216 , Diazepam 8-carbolines which effect agonist actions (i. ZK-93423, H1 and H2 are hydrogen bond donating groups indicated by the arrows in the left (yellow) and right (orange) hand portions, respectively. L2 and L3 are areas of lipophilic interaction indicated by the arrows on the top right (redorange) and left (cyan), respectively. S1 and S2 are areas of negative interaction shown in purple.
  16. Here we are studying how betacarbolines fit in the lipopohilic pocket. The excluded receptor volume was generated by using the MVOL option of SYBYL 5.22 by subtracting the union of the volume of the “actives” from the union of volume of the “inactives”.
  17. Using 166 ligands from 9 different families a binding site was proposed and included volumes were build using ligands with had good binding affinities.
  18. Figure 6: Overlap between pairs of included volumes derived from receptor subtype selective ligands: a) a1 and a2 , b) a2 and a3 , c) a4 and a6 , d) a1 and a6, e) a1 and a5 . Yellow color indicates overlapping regions and each grid measures 4 Å in width and height. In order to provide the connection between this figure and other figures, f) shows diazepam and the descriptors of the unified pharmacophore model depicted in the included volume requirement of the a1 subtype.
  19. 8-substituted
  20. 2.74 kcal/mol higher energy in syn conformation of ester for Ro-4513 ( N=N=N at 8 position , ethyl ester , CO at 5) WHAT IS ENERGY DIFFERENCE IN RING A VERSUS B
  21. Develop Pharmacophore Models 􀁦 Create GASP Models 􀁦 Create GALAHAD Models 􀁦 Align Compounds to GALAHAD Models Search Databases 􀁦 Modify 3D Queries 􀁦 Conduct Database Searches
  22. A2/a3 selective ligands aligned Perform a receptor surface analysis 3D QSAR
  23. serotonin–norepinephrine–dopamine reuptake inhibitor Coding of features: blue sphere, positive ionizable; pink spheres, H-bond acceptor; green spheres, hydrophobic; orange sphere, aromatic….maestro created 3 pharmacophore….merged to one. For the triple reuptake inhibitors. Blockade of hERG K + channels is widely regarded as the predominant cause of Cardiac arrhythmia …. data for a diverse set of 194 potent uncharged hERG actives, we propose a pharmacophore for neutral hERG blockers …..used as a screen…. Pharmacophores for Uncharged Human Ether-a-go-go-Related Gene (hERG) Blockers ring…MOE used to build multiple pharmacophores….then the best pharmacophores with fewest (5) green (hydrophobe/aromatic) and red (hydrogen bond acceptor)
  24. Homology modeling , also known as comparative modeling of protein refers to constructing an atomic-resolution model of the " target " protein from its amino acid sequence and an experimental three-dimensional structure of a related homologous protein (the " template ").
  25. site directed mutagenesis studies have led to the conclusion that the GABA receptor is between an alpha and beta subunit and the Bz receptor is lied between an alpha and gamma subunit. This has made it difficult to crystalize this pentameric protein complex.
  26. Brejc in 2001 reports the crystal structure of homopentamer with a ligand in the binding site. This was verified as the residues implicated with agonist binding in nAChR and AChBP were conserved in the receptor. [site directed mutagenesis]
  27. Crystal structure of a single alpha subunit of the acetylcholine binding protein.. This was verified as the residues implicated with agonist binding in nAChR and AChBP were conserved in the receptor. [site directed mutagenesis]
  28. . The ligand binding domains of human GABA A receptors (a1, a2, a3, a5, b2, and g2) were obtained from the Research Collaboratory for Structural Bioinformatics (RCSB). Originated in 1971 at Brookhaven National Laboratories, this is the home of the Protein Data Bank.
  29. Thread amino acid using iterative magic fit.
  30. dihedral angles ψ against φ of amino acid residues in protein structure . [1] It shows the possible conformations of ψ and φ angles for a polypeptide . Root mean square deviation
  31. Could our compounds be racemic? H NMR or HPLC to elucidate…DONE BY NMR